Pharmaceutical market growth to slow in '07

Share this article:
Growth of the global pharmaceutical market is expected to slow next year, according to prescription drug tracking firm IMS Health. Overall global market growth will be between 5% and 6% for 2007, compared with 6% and 7% for 2006, according to IMS Health’s 2007 Pharmaceutical Market Forecast. US market growth is predicted to slow to between 4% and 5%, compared to between 6% and 7% expected in 2006. The IMS Health study estimated that between 25 and 35 new products would be introduced to the US market in 2007, comparable to the 30 expected launches for this year. Meanwhile, prescription drugs with combined sales of $10 billion will go off patent in 2007, comparable to the $19 billion in product sales facing generic competition in the US in 2006, IMS Health said. Oncology products are expected to reach up to $45 billion in value in 2007, contributing to nearly 20% of total market growth, the report said. Lipid-lowering drugs will grow to $33 billion, reflecting an estimated 1% to 2% growth in 2007, down from between 7% to 8% this year. “In 2007, the market still will be absorbing changes that have defined a new economic reality, one in which growth is shifting from mature markets to emerging ones,” said Murray Aitken, IMS Health SVP, corporate strategy, in a statement. “New product adoption is not keeping pace with the loss of patent protection by established products, specialty and niche products are playing a larger role and regulators, payers and consumers are more carefully weighing the risk/benefit factors of pharmaceuticals,” Aitken said.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...